Please login to the form below

Diversity in clinical trials needs to extend beyond COVID-19 vaccine trials

First up, the hard truth is that clinical trial populations are not diverse. People of certain ethnicities, females and the elderly are typically underrepresented in clinical research. And you might ask, “why?”

While demographics that make us diverse might not be direct barriers themselves, factors relating to them can mean people are unable to take part in clinical trials. For example:

  • Religious and cultural barriers that are more prominent among ethnic minorities
  • Travel and mobility are more likely to be challenging among the elderly
  • Mistrust in the pharmaceutical industry based on historical treatment of ethnic minorities

So yes, there are challenges that lead to a lack of diversity in clinical trials. But there’s still a need to overcome them.

The science behind diversity

You might be wondering why it’s so important for clinical trials to be diverse anyway. Well, people respond to treatments differently based on their ethnicity, gender and age. And on top of that, we think results like these speak for themselves:

  • Multiple sclerosis (MS) is three times more common in women than in men
  • Developing type 2 diabetes is reported to be as much as 6 times higher in South Asians than in Europeans
  • The prevalence of high blood pressure in African Americans is the highest in the world and develops at younger ages than other groups in the U.S

So, for example, if a clinical trial is investigating a treatment for MS, yet the majority of the participants are men, is it really going to help the MS population when women are mostly affected? If clinical trials are investigating high blood pressure treatments, yet do not include African American participants, are the results really going to be representative?

So, firstly, clinical trials need to be diverse to ensure the treatment represents the intended disease population.

Corporate responsibility

All companies have a corporate responsibility to ensure diversity. This includes employees at all levels, who should be truly representative and reflective of the people the organisation serves - this is particularly relevant for pharmaceutical companies! And while diversity itself is important, so is a culture that encourages diversity.

Maximising understanding of patients and consumers

It seems obvious that a diverse workplace would lead to a better understanding of the positioning of a diverse consumer base. But if pharma companies maximise how much they understand and connect with a diverse audience, they’ll be more likely to achieve success.

Increasing trust in the general public

There’s a lack of trust in the pharma industry in general, but it’s more pronounced in certain ethnic groups than white people. For example, the way certain ethnic groups have been treated throughout history has left a lasting effect on people’s perceptions of clinical research throughout the world. So, damage needs to be repaired from previous scandals that have led to pharmaceutical companies having a negative reputation, and work needs to be done with well-considered strategies to help rebuild trust and relationships. Because trust is key, and without it, pharma will achieve limited success.

So, these are the reasons why diversity needs to improve in clinical trials. Wondering where the issue

has come from and how to overcome it? We’ve got the need-to-know information in our white paper, here.

This blog was originally published here:

13th October 2020

Share

Tags

Company Details

COUCH Health

+44 (0) 330 995 0656

Contact Website

Address:
Suite 2.10, Jactin House
24 Hood Street
Manchester
M4 6WX
United Kingdom

Latest content on this profile

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need unconscious bias training.”
COUCH Health
How do ethnic minority groups in the U.S. view clinical trials?
This year, we decided to do the same with ethnic minority communities over in the United States (U.S.) too. Ultimately, we wanted to explore attitudes towards clinical trials from these communities, understand the barriers in participation, and determine what factors may influence people’s decisions to take part.
COUCH Health
Three things to consider when using social listening research for patient recruitment
We are looking at how patient research can power your patient recruitment campaign. A look into social listening follows on from this blog perfectly, offering a stronger and more authentic alternative to relying on data trends to guide your activities. So, let’s get started…
COUCH Health
4 ways mobile ethnography studies can elevate your patient insights
How can we achieve more real-life, in-the-moment insights from different groups to understand their thoughts and behaviours? This is where ethnography studies come in.
COUCH Health
#DemandDiversity: We’re calling on the clinical trials industry to include us all
The lack of diversity in clinical trials is something we’ve spoken about time and time again. By now, you might think we sound a bit like a broken record. But, the fact is, many people still aren’t aware of the underrepresentation, especially those who don’t work in the industry. Do you think if the clinical research industry could see the people they were leaving out of clinical trials, and hear how they felt about being underrepresented, it would make a difference?
COUCH Health
Include Us All in Your Clinical Trials

COUCH Health